17d3d480-5503-419e-92cd-cbc7db9659d2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- HEDGEHOG_SIGNALING+0.450
- ANGIOGENESIS+0.440
- MYOGENESIS+0.380
- UV_RESPONSE_DN+0.380
- ALLOGRAFT_REJECTION+0.340
- APICAL_SURFACE+0.340
- INFLAMMATORY_RESPONSE+0.330
- APICAL_JUNCTION+0.320
- KRAS_SIGNALING_DN+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V1-0.570
- MYC_TARGETS_V2-0.560
- E2F_TARGETS-0.490
- MTORC1_SIGNALING-0.480
- DNA_REPAIR-0.460
- FATTY_ACID_METABOLISM-0.460
- CHOLESTEROL_HOMEOSTASIS-0.420
- PEROXISOME-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.929 |
| 2 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.928 |
| 3 | SRR975557 | — | — | 0.928 |
| 4 | SRR9879291 | — | cohortMD2 | 0.927 |
| 5 | DRR168582 | — | — | 0.922 |
| 6 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.920 |
| 7 | aMVAC.P_004_TURBT_S222 | — | — | 0.920 |
| 8 | e72bd7b6-c350-4f96-a633-8bf86079f57c | — | — | 0.917 |
| 9 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.915 |
| 10 | SRR15069598 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |